Qinghua Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qinghua Luo has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Fang Li
Department of Neurology, the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, P.R. China
3 shared publicationsInge Tomic
Department of Neurology, Saarland University, Homburg/Saar, Germany
2 shared publications- Jianglong Tu
Department of Neurology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, China
2 shared publications Wenlin Hao
Department of Neurology, Saarland University, Homburg/Saar, Germany
2 shared publications- Yang Liu
Saarland University
2 shared publications Zi-Ying He
Department of Neurology, the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, P.R. China
2 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by Springer Nature in The Journal of Headache and Pain
IL-17A/IL-17RA signaling drives microglial mtDNA-cGAS/STING axis to promote synaptic and cognitive impairment in chronic migraine
- 3 September 2026
- Published by Springer Nature in The Journal of Headache and Pain
Open AccessIL-17A/IL-17RA signaling drives microglial mtDNA-cGAS/STING axis to promote synaptic and cognitive impairment in chronic migraine
- Open Access
- 25 April 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (4) , e71423
Endothelial NAD + depletion drives vascular senescence and neuroinflammation via mtDNA‐cGAS/STING‐CD38 signaling in Alzheimer's disease
BACKGROUND: Endothelial dysfunction has emerged as early and pivotal event in Alzheimer's disease (AD), yet the molecular mechanisms linking vascular aging to neuroinflammation remain elusive. METHODS: We used APP/PS1 mice and amyloid beta (Aβ)–challenged brain endothelial cells (BECs) to understand the mechanisms of nicotinamide adenine dinucleotide (NAD + ) deficiency, and its relationship with endothelial senescence and neuroinflammation in AD pathology. Nicotinamide riboside supplementation was administered to APP/PS1 mice to determine whether restoration of NAD + homeostasis mitigates AD‐related vascular and inflammatory pathology. RESULTS: NAD + deficiency induced voltage‐dependent anion channel 1 (VDAC1) oligomerization, mitochondrial DNA (mtDNA) leakage, and cGAS/STING‐IRF3 activation, promoting endothelial senescence and SASP production with NAD + ‐consuming enzyme CD38 upregulation. Senescent BECs triggered IL‐6‐dependent microglial activation. NR treatment restored mitochondrial integrity, suppressed cGAS‐STING signaling, and reduced neuroinflammation, improving vascular function and cognition. DISCUSSION: Aβ‐driven NAD + deficiency initiates a VDAC1‐mtDNA‐cGAS/STING cascade that promotes endothelial senescence and neurovascular inflammation in AD pathology, and amplifies neuroinflammation through BEC–microglia crosstalk, highlighting NAD + restoration as a promising AD therapeutic strategy.
- 25 April 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (4) , e71423
Open AccessEndothelial NAD + depletion drives vascular senescence and neuroinflammation via mtDNA‐cGAS/STING‐CD38 signaling in Alzheimer's disease
BACKGROUND: Endothelial dysfunction has emerged as early and pivotal event in Alzheimer's disease (AD), yet the molecular mechanisms linking vascular aging to neuroinflammation remain elusive. METHODS: We used APP/PS1 mice and amyloid beta (Aβ)–challenged brain endothelial cells (BECs) to understand the mechanisms of nicotinamide adenine dinucleotide (NAD + ) deficiency, and its relationship with endothelial senescence and neuroinflammation in AD pathology. Nicotinamide riboside supplementation was administered to APP/PS1 mice to determine whether restoration of NAD + homeostasis mitigates AD‐related vascular and inflammatory pathology. RESULTS: NAD + deficiency induced voltage‐dependent anion channel 1 (VDAC1) oligomerization, mitochondrial DNA (mtDNA) leakage, and cGAS/STING‐IRF3 activation, promoting endothelial senescence and SASP production with NAD + ‐consuming enzyme CD38 upregulation. Senescent BECs triggered IL‐6‐dependent microglial activation. NR treatment restored mitochondrial integrity, suppressed cGAS‐STING signaling, and reduced neuroinflammation, improving vascular function and cognition. DISCUSSION: Aβ‐driven NAD + deficiency initiates a VDAC1‐mtDNA‐cGAS/STING cascade that promotes endothelial senescence and neurovascular inflammation in AD pathology, and amplifies neuroinflammation through BEC–microglia crosstalk, highlighting NAD + restoration as a promising AD therapeutic strategy.
- Open Access
- 11 March 2026
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 27 (1) , 76
S100A11 regulates microglial inflammatory response in neuropathic pain via H3K27ac-TFEB-mitochondrial autophagy axis
Neuropathic pain (NP) is tightly linked to spinal microglial overactivation, sustained neuroinflammation; however, the key molecular regulators and epigene
- 11 March 2026
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 27 (1) , 76
Open AccessS100A11 regulates microglial inflammatory response in neuropathic pain via H3K27ac-TFEB-mitochondrial autophagy axis
Neuropathic pain (NP) is tightly linked to spinal microglial overactivation, sustained neuroinflammation; however, the key molecular regulators and epigene
- Open Access
- 2 February 2026
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 11 (5)
Endovascular intervention and therapeutic plasma exchange in the treatment of cerebral venous thrombosis associated with thyrotoxicosis: illustrative case
BACKGROUND: Cerebral venous thrombosis (CVT) is a rare cerebrovascular disorder that predominantly affects younger individuals. Its development is influenced by multiple factors, including hypercoagulability, hemodynamic abnormalities, and venous vessel wall injury. Thyrotoxicosis is an uncommon but increasingly recognized predisposing factor for CVT. OBSERVATIONS: The authors present the case of a young female with thyrotoxicosis-induced CVT who achieved successful recovery following endovascular intervention and therapeutic plasma exchange (TPE). LESSONS: This report emphasizes the clinical importance of recognizing thyrotoxicosis as a risk factor for CVT, underscores the therapeutic potential of TPE in thyroid storm complicated by thrombosis, and provides clinical reference for endovascular intervention in the treatment of CVT. https://thejns.org/doi/10.3171/CASE25820
- 2 February 2026
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 11 (5)
Open AccessEndovascular intervention and therapeutic plasma exchange in the treatment of cerebral venous thrombosis associated with thyrotoxicosis: illustrative case
BACKGROUND: Cerebral venous thrombosis (CVT) is a rare cerebrovascular disorder that predominantly affects younger individuals. Its development is influenced by multiple factors, including hypercoagulability, hemodynamic abnormalities, and venous vessel wall injury. Thyrotoxicosis is an uncommon but increasingly recognized predisposing factor for CVT. OBSERVATIONS: The authors present the case of a young female with thyrotoxicosis-induced CVT who achieved successful recovery following endovascular intervention and therapeutic plasma exchange (TPE). LESSONS: This report emphasizes the clinical importance of recognizing thyrotoxicosis as a risk factor for CVT, underscores the therapeutic potential of TPE in thyroid storm complicated by thrombosis, and provides clinical reference for endovascular intervention in the treatment of CVT. https://thejns.org/doi/10.3171/CASE25820
- Open Access
- 21 June 2024
- Published by Taylor & Francis in Gut Microbes
- Vol. 16 (1) , 2363014
Modulation of Alzheimer’s disease brain pathology in mice by gut bacterial depletion: the role of IL-17a
The microbial composition in the gut undergoes alterations in both Alzheimer’s disease (AD) patients and mouse models.1-4 A prospective study of cognitively healthy individuals revealed that a decr...
- 21 June 2024
- Published by Taylor & Francis in Gut Microbes
- Vol. 16 (1) , 2363014
Open AccessModulation of Alzheimer’s disease brain pathology in mice by gut bacterial depletion: the role of IL-17a
The microbial composition in the gut undergoes alterations in both Alzheimer’s disease (AD) patients and mouse models.1-4 A prospective study of cognitively healthy individuals revealed that a decr...
- Open Access
- 31 July 2022
- Published by Wiley in Aging Cell
- Vol. 21 (8) , e13679
p38α‐MAPK‐deficient myeloid cells ameliorate symptoms and pathology of APP‐transgenic Alzheimer's disease mice
Alzheimer's disease (AD), the most common cause of dementia in the elderly, is pathologically characterized by extracellular deposition of amyloid‐β peptides (Aβ) and microglia‐dominated inflammatory activation in the brain. p38α‐MAPK is activated in both neurons and microglia. How p38α‐MAPK in microglia contributes to AD pathogenesis remains unclear. In this study, we conditionally knocked out p38α‐MAPK in all myeloid cells or specifically in microglia of APP‐transgenic mice, and examined animals for AD‐associated pathologies (i.e., cognitive deficits, Aβ pathology, and neuroinflammation) and individual microglia for their inflammatory activation and Aβ internalization at different disease stages (e.g., at 4 and 9 months of age). Our experiments showed that p38α‐MAPK‐deficient myeloid cells were more effective than p38α‐MAPK‐deficient microglia in reducing cerebral Aβ and neuronal impairment in APP‐transgenic mice. Deficiency of p38α‐MAPK in myeloid cells inhibited inflammatory activation of individual microglia at 4 months but enhanced it at 9 months. Inflammatory activation promoted microglial internalization of Aβ. Interestingly, p38α‐MAPK‐deficient myeloid cells reduced IL‐17a‐expressing CD4‐positive lymphocytes in 9 but not 4‐month‐old APP‐transgenic mice. By cross‐breeding APP‐transgenic mice with Il‐17a‐knockout mice, we observed that IL‐17a deficiency potentially activated microglia and reduced Aβ deposition in the brain as shown in 9‐month‐old myeloid p38α‐MAPK‐deficient AD mice. Thus, p38α‐MAPK deficiency in all myeloid cells, but not only in microglia, prevents AD progression. IL‐17a‐expressing lymphocytes may partially mediate the pathogenic role of p38α‐MAPK in peripheral myeloid cells. Our study supports p38α‐MAPK as a therapeutic target for AD patients.
- 31 July 2022
- Published by Wiley in Aging Cell
- Vol. 21 (8) , e13679
Open Accessp38α‐MAPK‐deficient myeloid cells ameliorate symptoms and pathology of APP‐transgenic Alzheimer's disease mice
Alzheimer's disease (AD), the most common cause of dementia in the elderly, is pathologically characterized by extracellular deposition of amyloid‐β peptides (Aβ) and microglia‐dominated inflammatory activation in the brain. p38α‐MAPK is activated in both neurons and microglia. How p38α‐MAPK in microglia contributes to AD pathogenesis remains unclear. In this study, we conditionally knocked out p38α‐MAPK in all myeloid cells or specifically in microglia of APP‐transgenic mice, and examined animals for AD‐associated pathologies (i.e., cognitive deficits, Aβ pathology, and neuroinflammation) and individual microglia for their inflammatory activation and Aβ internalization at different disease stages (e.g., at 4 and 9 months of age). Our experiments showed that p38α‐MAPK‐deficient myeloid cells were more effective than p38α‐MAPK‐deficient microglia in reducing cerebral Aβ and neuronal impairment in APP‐transgenic mice. Deficiency of p38α‐MAPK in myeloid cells inhibited inflammatory activation of individual microglia at 4 months but enhanced it at 9 months. Inflammatory activation promoted microglial internalization of Aβ. Interestingly, p38α‐MAPK‐deficient myeloid cells reduced IL‐17a‐expressing CD4‐positive lymphocytes in 9 but not 4‐month‐old APP‐transgenic mice. By cross‐breeding APP‐transgenic mice with Il‐17a‐knockout mice, we observed that IL‐17a deficiency potentially activated microglia and reduced Aβ deposition in the brain as shown in 9‐month‐old myeloid p38α‐MAPK‐deficient AD mice. Thus, p38α‐MAPK deficiency in all myeloid cells, but not only in microglia, prevents AD progression. IL‐17a‐expressing lymphocytes may partially mediate the pathogenic role of p38α‐MAPK in peripheral myeloid cells. Our study supports p38α‐MAPK as a therapeutic target for AD patients.